ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0188

Dasatinib and Quercetin Combination Increases Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy

Session Information

  • AKI: Mechanisms - 2
    November 07, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Battaglia-Vieni, Antonio, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
  • Marchant, Vanessa A, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
  • Tejedor, Lucia, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
  • García Caballero, Cristina, Inflammation and Immunopathology of Organs and Systems. University Hospital La Princesa, Madrid, Spain
  • Salguero, Elena Flores, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
  • Ruiz-torres, Maria P., Department of Systems Biology, University of Alcalá, Madrid, Spain
  • Rayego-Mateos, Sandra, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
  • Ortiz, Alberto, Instituto de Salud Carlos III, Madrid, Spain
  • Ruiz-Ortega, Marta, Molecular and Cellular Biology in Renal and Vascular Pathology. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
Background

Acute kidney injury (AKI) is a significant clinical concern, especially in elderly patients, due to its high morbidity, mortality, and risk of progression to chronic kidney disease (CKD). Cellular senescence contributes to AKI and CKD pathogenesis and is considered a potential therapeutic target. Senolytics, such as the combination of dasatinib and quercetin (D&Q), have shown beneficial effects in chronic disease models. However, their impact in AKI remains poorly understood. This study evaluates the effect of D&Q in an acute folic acid-induced nephropathy (FAN) mouse model.

Methods

Male mice were pretreated with dasatinib (5 mg/kg) and quercetin (50 mg/kg) before induction of AKI using a single intraperitoneal injection of folic acid (125 mg/kg). Kidney function was assessed 48 hours post-injury by measuring serum creatinine and blood urea nitrogen (BUN). Renal gene expression of injury markers (Lcn2, Havcr1), the senescence marker Cdkn1a (p21), and SASP-related genes were quantified by qPCR. Immunohistochemistry was used to evaluate p21-positive cells and Klotho protein levels in kidney tissue.

Results

D&Q treatment did not improve renal function following folic acid-induced injury. Creatinine and BUN levels were elevated similarly in both untreated and D&Q-treated FAN groups. D&Q pretreatment increased the expression of injury biomarkers (Lcn2, Havcr1), the senescence gene Cdkn1a, and multiple SASP components. The number of p21+ senescent cells remained unchanged between groups. Moreover, D&Q failed to prevent the folic acid-induced reduction in the anti-aging factor Klotho.

Conclusion

Contrary to expectations, senolytic treatment with D&Q did not protect against folic acid-induced AKI and instead exacerbated markers of kidney damage and senescence. These findings highlight the complexity of targeting senescence in acute settings and suggest caution when considering the use of D&Q in AKI patients.

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)